EcoDrugPlus

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSDNOG00000008337
Gene Symbol: CHRM3
4 Cross references
257 Possible Orthologues:

Cholinergic Receptor Muscarinic 4

Ensembl ID : ENSDNOG00000043079
Gene Symbol: CHRM4
4 Cross references
186 Possible Orthologues:

Cholinergic Receptor Muscarinic 5

Ensembl ID : ENSDNOG00000016072
Gene Symbol: CHRM5
4 Cross references
264 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSDNOG00000047945
Gene Symbol: CHRNA3
4 Cross references
202 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 4 Subunit

Ensembl ID : ENSDNOG00000043797
Gene Symbol: CHRNA4
2 Cross references
206 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSDNOG00000014261
Gene Symbol: CHRNB2
2 Cross references
198 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSDNOG00000043001
Gene Symbol: CHRNB4
4 Cross references
199 Possible Orthologues:

Chymase 1

Ensembl ID : ENSDNOG00000043694
Gene Symbol: CMA1
4 Cross references
317 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSDNOG00000047767
Gene Symbol: F2R
4 Cross references
330 Possible Orthologues:

Coagulation Factor Ii, Thrombin

Ensembl ID : ENSDNOG00000012528
Gene Symbol: F2
2 Cross references
86 Possible Orthologues:

Coagulation Factor Iii, Tissue Factor

Ensembl ID : ENSDNOG00000017530
Gene Symbol: F3
4 Cross references
246 Possible Orthologues:

Coagulation Factor Vii

Ensembl ID : ENSDNOG00000006958
Gene Symbol: F7
2 Cross references
203 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).